MYRIAD GENETICS, INC. Restricted Cash, Current
MYRIAD GENETICS, INC. (MYGN) had Restricted Cash, Current of $8.60 million as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2025-02-28
- 2024-12-31: Restricted Cash, Current $8.60M.
- 2023-12-31: Restricted Cash, Current $1.20M.
- 2022-12-31: Restricted Cash, Current $2.00M.
- 2021-12-31: Restricted Cash, Current $1.00M.
| Period end | Restricted Cash, Current |
|---|---|
| 2024-12-31 | $8.60M 10-K · filed 2025-02-28 |
| 2023-12-31 | $1.20M 10-K · filed 2025-02-28 |
| 2022-12-31 | $2.00M 10-K · filed 2024-02-28 |
| 2021-12-31 | $1.00M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |